BMC Biotechnology (Oct 2022)

Identification of a novel fully human anti-toxic shock syndrome toxin (TSST)-1 single-chain variable fragment antibody averting TSST-1-induced mitogenesis and cytokine secretion

  • Mahdieh Soezi,
  • Somayeh Piri-Gavgani,
  • Mostafa Ghanei,
  • Mir Davood Omrani,
  • Behnoush Soltanmohammadi,
  • Kamran Pooshang Bagheri,
  • Reza Ahangari Cohan,
  • Farzam Vaziri,
  • Seyed Davar Siadat,
  • Abolfazl Fateh,
  • Shohreh Khatami,
  • Masoumeh Azizi,
  • Fatemeh Rahimi-Jamnani

DOI
https://doi.org/10.1186/s12896-022-00760-8
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Background Staphylococcal superantigens are virulence factors that help the pathogen escape the immune system and develop an infection. Toxic shock syndrome toxin (TSST)-1 is one of the most studied superantigens whose role in toxic shock syndrome and some particular disorders have been demonstrated. Inhibiting TSST-1 production with antibiotics and targeting TSST-1 with monoclonal antibodies might be one of the best strategies to prevent TSST-1-induced cytokines storm followed by lethality. Results A novel single-chain variable fragment (scFv), MS473, against TSST-1 was identified by selecting an scFv phage library on the TSST-1 protein. The MS473 scFv showed high affinity and specificity for TSST-1. Moreover, MS473 could significantly prevent TSST-1-induced mitogenicity (the IC50 value: 1.5 µM) and cytokine production. Conclusion Using traditional antibiotics with an anti-TSST-1 scFv as a safe and effective agent leads to deleting the infection source and preventing the detrimental effects of the toxin disseminated into the whole body.

Keywords